Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group.

Shepherd, Frances A.; Ginsberg, Robert J.; Haddad, Raymond; Feld, Ronald; Sagman, Uri; Evans, William K.; DeBoer, Gerrit; Maki, Ellen

doi:10.1200/jco.1993.11.8.1592

Cited by 71 publications

(24 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In order to verify the role of angiogenic phenomenon also in SCLC, as we had previously performed in a large series of non-small cell lung tumours (Fontanini et al, 1997a,b,c), a series of 75 SCLC was investigated, with particular reference to vascular count, VEGF and p53 expression. In our series we observed that nodal metastasis and tumour stage were important predictors of poor prognosis, as already reported in previous studies (Shepherd et al, 1993).…”

Section: Discussionsupporting

confidence: 90%

A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma

et al. 2002

View full text Add to dashboard Cite

It has been widely demonstrated that neo-angiogenesis and its mediators (i.e. vascular endothelial growth factor), represent useful indicators of poor prognosis in non small cell lung carcinoma. In order to verify whether neovascularization and vascular endothelial growth factor may be considered useful markers of clinical outcome also in the small cell lung cancer subgroup, we retrospectively investigated a series of 75 patients with small cell lung carcinoma treated by surgery between 1980 and 1990. Immunohistochemically-detected microvessels and vascular endothelial growth factor expressing cells were significantly associated with poor prognosis, as well as with nodal status and pathological stage. In fact, patients whose tumours had vascular count and vascular endothelial growth factor expression higher than median value of the entire series (59 vessels per 0.74 mm 2 and 50% of positive cells, respectively), showed a shorter overall and disease-free survival ( P =0.001, P =0.001; P =0.008, P =0.03). Moreover, the presence of hilar and/or mediastinal nodal metastasis and advanced stage significantly affected overall and disease-free interval ( P =0.00009, P =0.00001; P =0.0001, P =0.00001). At multivariate analysis, only vascular endothelial growth factor expression retained its influence on overall survival ( P =0.001), suggesting that angiogenic phenomenon may have an important role in the clinical behaviour of this lung cancer subgroup. British Journal of Cancer (2002) 86 , 558–563. DOI: 10.1038/sj/bjc/6600130 www.bjcancer.com © 2002 Cancer Research UK

show abstract

Section: Discussionsupporting

confidence: 90%

A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Median survival of 68 months and a 5-year survival of 63% in this subgroup are promising and point to the efficacy of this approach also in patients in stage IIIA (N2). Different to our findings with preoperative chemoradiation, earlier investigations with chemotherapy alone followed by surgery had been disappointing for mediastinal N2-disease (IIIA(N2)) (Meyer et al, 1984;Shepherd et al, 1993).…”

Section: Discussioncontrasting

confidence: 55%

Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: Long-term results of a phase II trial

Eberhardt¹,

et al. 1999

View full text Add to dashboard Cite

Summary Following mediastinoscopy, a prognostically orientated multimodality approach was chosen in selected small-cell lung cancer (SCLC) patients with hyperfractionated accelerated chemoradiotherapy (Hf-RTx) and definitive surgery (S). Stage IB/IIA patients had four cycles of cisplatin/etoposide (PE) and surgery. Stage IIB/IIIA patients had three cycles PE followed by one cycle concurrent chemoradiation including Hf-RTx and surgery. Most stage IIIB patients were not planned for surgery and had CTx followed by sequential RTx or one cycle concurrent CTx/RTx. Of 46 consecutive patients (stage IB six, IIA two, IIB/IIIA 22, IIIB 16) 43 (94%) showed an objective response. Twentythree of patients (72%) planned for inclusion of S were completely resected (R0) (IB 6/6, IIA 2/2, IIB/IIIA 13/22, IIIB 2/2). Overall toxicity was acceptable -one patient died of septicaemia, no perioperative deaths occurred. Median follow-up of patients alive (n = 21) is 52 months (30+ -75+). Median survival and 5-year survival rate of all patients are 36 months and 46%, in R0 patients 68 months and 63% (R0-IIB/IIIA/IIIB: not yet reached and 67%). This multimodality treatment including surgery proved highly effective with 100% local control and remarkable long-term survival after complete resection, even in locally advanced SCLC stages IIB/IIIA patients.

show abstract

“…The IASLC staging criteria were expected to better predict prognosis according to cancer stage (16). Some studies have also highlighted the difference in prognosis within LD patients taking into account mediastinal lymphadenopathy (17). In a study performed in 1990, the authors concluded that it was necessary to optimize SCLC classification (18).…”

Section: Discussionmentioning

confidence: 99%

New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases

Dayen¹,

Debieuvre²,

Molinier³

et al. 2017

J. Thorac. Dis.

View full text Add to dashboard Cite

Background: The French College of General Hospital Respiratory Physicians conducted two studies that consecutively included all patients followed in participating general hospitals for primary small cell (SCLC) or non-small cell (NSCLC) lung cancer diagnosed in 2000 and 2010. These studies allow descriptive statistics and outcome assessment for SCLC and NSCLC separately and comparison over a 10-year period.Methods: A standardised form was completed for each patient at inclusion. Then, vital status was collected.

show abstract

Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group.

Cited by 71 publications

References 15 publications

A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma

A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma

Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: Long-term results of a phase II trial

New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases

Contact Info

Product

Resources

About